Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precigen, Inc. (PGEN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Precigen is a Nasdaq Global Select Market–listed biopharmaceutical company, and its filings offer detailed insight into the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP), ongoing clinical programs, capital structure, and material agreements.
Current reports on Form 8-K document key corporate events, such as the announcement of financial results, entry into material definitive agreements, and capital transactions. For example, recent 8-K filings describe a senior secured term loan facility of up to $125 million with entities managed by Pharmakon Advisors, LP, a commercial supply agreement for PAPZIMEOS with an external manufacturing partner, and the conversion of Series A Convertible Perpetual Preferred Stock into common stock. Other 8-Ks cover shareholder meeting results, including approvals of equity incentive plan amendments and increases in authorized common shares.
Periodic reports such as annual and quarterly filings (Forms 10-K and 10-Q, when available) provide broader context on Precigen’s financial condition, risk factors, research and development activities, and commercialization efforts. These documents typically include discussions of PAPZIMEOS approval and launch, the company’s pipeline programs like PRGN-2009 and PRGN-3006, and the impact of financing arrangements and warrant liabilities on the balance sheet.
Investors can also review any Form 4 or related insider transaction filings, when present, to understand equity transactions by directors, officers, or significant shareholders. On Stock Titan, AI-powered tools summarize complex filings, highlight key terms in loan and supply agreements, and help explain the implications of capital structure changes, regulatory milestones, and other material events disclosed in Precigen’s SEC submissions.
PRECIGEN, INC. director and major shareholder Randal J. Kirk reported the vesting and exercise of 143,678 restricted stock units into an equal number of shares of common stock at an exercise price of $0.00 per share on March 13, 2026.
The shares are held indirectly through the R.J. Kirk Declaration of Trust, which now holds 81,781,816 shares of Precigen common stock. Additional Form 4 entries list indirect holdings in various trusts, LLCs and related entities that Mr. Kirk controls, with beneficial ownership disclaimed except for any pecuniary interest.
PRECIGEN, INC. director Nancy H. Agee exercised restricted stock units that converted into common shares. On March 13, 2026, 71,839 RSUs vested in full, with each RSU representing one share of Precigen common stock. Following the conversion, she directly holds 305,776 shares of common stock.
This is a compensation-related equity vesting rather than an open-market purchase or sale, and there were no shares reported as sold in connection with this transaction.
PRECIGEN, INC. director Cesar L. Alvarez exercised restricted stock units that had fully vested into common shares. On March 13, 2026, 71,839 RSUs vested in full and were converted into the same number of common shares at no cash exercise price. Following this compensation-related exercise-and-hold transaction, he directly owned 782,909 shares of Precigen common stock.
PRECIGEN, INC. director Frank Steven reported the vesting and exercise of restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units converted into 71,839 shares of Precigen common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.
The footnotes state that each RSU represented a contingent right to receive one share of common stock and that the RSUs vested in full on March 13, 2026. After the transaction, Steven directly held 1,226,391 shares of Precigen common stock, with no remaining RSU position shown in this filing.
PRECIGEN, INC. director Vinita D. Gupta reported the vesting and exercise of restricted stock units into common shares. On March 13, 2026, 71,839 RSUs, each representing the right to receive one share of Precigen common stock, vested in full and were converted into 71,839 common shares at no exercise price. Following this transaction, Gupta holds 666,027 shares of Precigen common stock directly, reflecting a routine compensation-related equity acquisition rather than an open-market purchase or sale.
Precigen, Inc. director Fred Hassan exercised restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units vested in full, with each unit converting into one share of Precigen common stock at an exercise price of $0.00 per share.
Following this derivative exercise, Hassan directly owned 1,243,239 shares of Precigen common stock. The filing shows acquisitions only, with no open-market purchases or sales reported in this transaction.
PRECIGEN, INC. director Jeffrey B. Kindler received common stock through the vesting of previously granted restricted stock units. On March 13, 2026, 71839 RSUs vested in full, converting into 71839 shares of common stock at no exercise price. Following this compensation-related transaction, he directly holds 202100 shares of Precigen common stock, with no reported open-market purchases or sales and no remaining derivative holdings in this filing.
PRECIGEN, INC. director James S. Turley reported the vesting and conversion of restricted stock units into common shares. On March 13, 2026, 71,839 restricted stock units vested in full and were exercised, delivering 71,839 shares of common stock at no cash exercise price.
Following this compensation-related transaction, Turley directly owned 685,417 shares of Precigen common stock. The filing reflects an increase in equity holdings through RSU vesting rather than any open-market purchase or sale.
PRECIGEN, INC. director and greater-than-10% owner Randal J. Kirk reported compensation-related equity awards and updated indirect holdings. On 2026-03-10, an entity he controls, R.J. Kirk Declaration of Trust, received 71,225 restricted stock units, each representing one share of common stock that vests on the one-year anniversary of grant if he continues providing services.
The same trust was also granted 82,147 stock options for common stock at an exercise price of $3.51 per share, expiring on 2036-03-10, and 28,490 shares of common stock at $3.51 per share, bringing its indirect common stock holdings to 81,638,138 shares.
The filing also lists indirect common stock positions held through multiple entities Mr. Kirk controls, including JPK 2008 LLC with 477,492 shares, JPK 2009 LLC with 3,609,057 shares, JPK 2012 LLC with 1,615,634 shares, MGK 2008 LLC with 476,529 shares, MGK 2009 LLC with 3,785,116 shares, MGK 2011 LLC with 1,594,338 shares, ZSK 2008 LLC with 566,162 shares, ZSK 2009 LLC with 341,189 shares, Kellie L. Banks (2009) Long Term Trust with 447,773 shares, Kapital Joe, LLC with 4,598,044 shares, Lotus Capital (2000) Company, Inc. with 1,403 shares, Third Security, LLC with 6,085,471 shares, Parkview 2020 Limited Partnership with 1,096,686 shares, Sunset 2020 LLC with 14,597,161 shares, and shares held by his spouse totaling 1,144,481 shares. The footnotes state Mr. Kirk controls these entities and that shares held by them may be deemed beneficially owned by him, while he disclaims beneficial ownership except to the extent of any pecuniary interest.
PRECIGEN, INC. director James S. Turley reported equity compensation awards rather than open-market trades. On March 10, 2026, he received 35,612 restricted stock units and options for 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. He also received 17,806 shares of common stock issued in lieu of a cash annual retainer of $62,500. The restricted stock units vest in full on March 10, 2027. Following these awards, his direct common stock holdings increased to 613,578 shares.